Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hira Lal

Showing results (171-180 of 172) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 172 results.
Scientific Reports|October 3, 2023
A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adultsPrasad S Kulkarni, Bhagwat Gunale, Sunil Kohli, et al.
The Lancet Regional Health. Southeast Asia|January 17, 2023
Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled studyPrasad S Kulkarni, Abhijit Kadam, Sheela Godbole, et al.
Pageof 18

Showing results (171-180 of 172) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 172 results.
Scientific Reports|October 3, 2023
A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adultsPrasad S Kulkarni, Bhagwat Gunale, Sunil Kohli, et al.
The Lancet Regional Health. Southeast Asia|January 17, 2023
Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled studyPrasad S Kulkarni, Abhijit Kadam, Sheela Godbole, et al.
Pageof 18